

## Lupus Therapeutics Board of Directors:

**Joseph Craft, MD** is is Paul B. Beeson Professor of Medicine and Professor of Immunobiology at the Yale School of Medicine, and past chief of the Section of Rheumatology at Yale.

**Kelly McVearry, PhD, MA, Ed.M.** has two decades of experience leading the design, development, due diligence and commercialization of life science and information technologies.

**William J. Wolfe**, Co-founder, Chairman and CEO of First Washington Realty, Inc., a privately held real estate investment advisory firm specializing in ownership of neighborhood and community shopping centers in major metropolitan areas.

**Brian Kotzin, MD** has been committed to patient care, research, and teaching during his 25-year academic career.

**Joseph Mauriello**, Former Deputy Chairman & COO of KPMG, after 40 years of leadership positions.

**Jennie DeScherer** is an active Board member of the Lupus Research Alliance having helped lead its predecessor organizations — S.L.E. Lupus Foundation (S.L.E.) and the Lupus Research Institute (LRI) — since their early years.

**Alexander von Perfall** joined Royalty Pharma in 2009 as Vice President, Investor Relations & Public Affairs.

**Cantey Boyd** serves as a Managing Director of Baker Brothers Investments, a fund management company focused on long-term investments in life-sciences companies.

**Daniel J. Wallace, MD,FACP,MACR** is a board-certified internist and rheumatologist. A Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA, he is the Associate Director of the Rheumatology Fellowship Program at Cedars-Sinai Medical Center where he also serves on the Board of Governors.

**Kenneth M. Farber** serves as the President and CEO of the Lupus Research Alliance.

**Albert Roy** serves as the Executive Director of Lupus Therapeutics.